Genetic counseling in melanoma
- Funding/Support: The research at the Melanoma Unit in Barcelona is partially funded by Grants 03/0019, 05/0302, 06/0265, and 09/1393 from Fondo de Investigaciones Sanitarias, Spain; by the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain; by the AGAUR 2009 SGR 1337 of the Catalan Government, Spain; by the European Commission under the 6th Framework Programme, Contract No: LSHC-CT-2006-018702 (GenoMEL); and by the National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115).
- Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of data; or in the preparation, review, or approval of the manuscript.
Address correspondence and reprint requests to: Celia Badenas, PhD, Biochemical and Molecular Genetics Service, Melanoma Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain, or email: firstname.lastname@example.org.
Genetic counseling may be offered to families with melanoma and to individuals with multiple melanomas to better understand the genetic susceptibility of the disease, the influence of environmental factors, the inheritance of the risk, and behavior that decreases the risk of dying from melanoma, including specific dermatological follow-up such as total body photography and digital dermoscopy. Genetic testing may be offered to those individuals with more than a 10% chance of being a carrier of a mutation. This risk varies according to the incidence of melanoma in the country and sun behavior. In countries with a low-medium incidence of melanoma, genetic testing should be offered to families with two cases of melanoma or an individual with two primary melanomas. In countries with a high incidence, families with three cases of melanoma, with two melanomas and one pancreatic adenocarcinoma, or patients with three primary melanomas, may benefit from genetic testing.